Mitochondrial ATP synthase disorders: Molecular mechanisms and the quest for curative therapeutic approaches  by Kucharczyk, Roza et al.
Biochimica et Biophysica Acta 1793 (2009) 186–199
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrReview
Mitochondrial ATP synthase disorders: Molecular mechanisms and the quest for
curative therapeutic approaches
Roza Kucharczyk a,1, Michael Zick b,1, Maïlis Bietenhader a, Malgorzata Rak a,2, Elodie Couplan c,d,e,f,
Marc Blondel c,d,e,f, Stéphane-Duvezin Caubet a, Jean-Paul di Rago a,⁎
a Institut de Biochimie et Génétique Cellulaires, CNRS-Université Bordeaux2, Bordeaux 33077, France
b Adolf-Butenandt-Institut für Physiologische Chemie, Ludwig-Maximilians-Universität München, Butenandtstr. 5, 81377 München, Germany
c INSERM U613, Brest, F-29200, France
d Univ Brest, Faculté de Médecine et des Sciences de la Santé, UMR-S613, Brest, F-29200, France
e Etablissement Français du Sang (EFS) Bretagne, Brest, F-29200, France
f CHU Brest, Hop Morvan, Laboratoire de Génétique Moléculaire, Brest, F-29200, France⁎ Corresponding author. Tel.: + 33 5 56 99 90 43.
E-mail address: jp.dirago@ibgc.u-bordeaux2.fr (J.-P.
1 These authors contributed equally and are listed in
2 Present address: Department of Biological Sciences, C
NY 10027, USA.
0167-4889/$ – see front matter © 2008 Elsevier B.V. Al
doi:10.1016/j.bbamcr.2008.06.012a b s t r a c ta r t i c l e i n f oArticle history: In mammals, the majority o
Received 19 March 2008
Received in revised form 6 June 2008
Accepted 11 June 2008
Available online 20 June 2008
Keywords:
ATP synthase
Mitochondrial diseases
Drug screening
Yeast
Mitochondrial biogenesis
NARP and MILS syndromesf cellular ATP is produced by the mitochondrial F1FO-ATP synthase through an
elaborate catalytic mechanism. While most subunits of this enzymatic complex are encoded by the nuclear
genome, a few essential components are encoded in the mitochondrial genome. The biogenesis of this multi-
subunit enzyme is a sophisticated multi-step process that is regulated on levels of transcription, translation
and assembly. Defects that result in diminished abundance or functional impairment of the F1FO-ATP
synthase can cause a variety of severe neuromuscular disorders. Underlying mutations have been identiﬁed
in both the nuclear and the mitochondrial DNA. The pathogenic mechanisms are only partially understood.
Currently, the therapeutic options are extremely limited. Alternative methods of treatment have however
been proposed, but still encounter several technical difﬁculties. The application of novel scientiﬁc approaches
promises to deepen our understanding of the molecular mechanisms of the ATP synthase, unravel novel
therapeutic pathways and improve the unfortunate situation of the patients suffering from such diseases.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Most of the energy needed by human cells is provided by
mitochondria in the form of ATP through oxidative phosphorylation
[1]. The ﬁnal stages of this process are catalyzed by an F1FO-type ATP
synthase located in the inner mitochondrial membrane. This enzyme,
also called complex V, utilizes the energy of an electrochemical proton
gradient across the inner membrane to catalyze the synthesis of ATP
fromADP and inorganic phosphate. This gradient is established during
oxygen reduction by a series of four respiratory complexes (I–IV)
embedded in the mitochondrial inner membrane.
Themitochondrial ATP synthase is a multi-subunit complex, with a
molecular mass of approximately 550,000Da. It has historically been
described in terms of a hydrophobic domain (FO) containing a proton
channel and a hydrophilic ATPase (F1) bearing the adenine nucleotide
processing sites [2–5]. Strong evidence supports a mechanism in
which H+ translocation from the intermembrane space to the matrixdi Rago).
alphabetical order.
olumbia University, New York,
l rights reserved.through FO is coupled to the rotation of a subcomplex of the enzyme
(the rotor) which in turn induces conformational changes in the F1
that favor the synthesis of ATP and its release from the enzyme.
The biogenesis of the mitochondrial ATP synthase is a sophisti-
cated process, which depends on the coordinated expression of the
nuclear andmitochondrial genomes, except in a few species, e.g. green
algae, inwhich thewhole enzyme is of nuclear origin [6]. In addition, a
number of ‘assembly factors’ not belonging to the ﬁnal enzyme
performs speciﬁc actions in the synthesis, transport toward the inner
membrane, and ﬁnally oligomerization of the individual ATP synthase
subunits.
This review focuses on human mitochondrial diseases associated
with primary deﬁciencies in the ATP synthase. A number of
epidemiological studies within the last decade have clearly demon-
strated that mitochondrial disorders are far more common than
previously appreciated [7,8]. In particular, ATP synthase defects may
be underdiagnosed in clinical practice, as they are often not
considered in the diagnostic approach in favor of more common
conditions (e.g. asphyxia, heart failure) [9]. Nevertheless, pronounced
defects of the ATP synthase of either nuclear or mitochondrial genetic
origin result in highly deleterious disorders of the neuromuscular
system that manifest primarily in children, very often shortly after
birth [10]. To date, no causal treatment (i.e. aiming to reverse the
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pathogenic mechanisms are certainly more complex than a mere
decrease in cell energy provision. Secondary effects, such as increased
production of free oxygen radicals (ROS), a decrease in the inter-
mediary metabolism, metabolic acidosis and probably further as yet
unrecognized dysfunctions, are likely to contribute to the pathogen-
esis of these diseases.
Various model systems have been designed to help elucidate the
molecular mechanisms of ATP synthase-based diseases and the search
for therapeutic solutions. Among these are transmitochondrial
cytoplasmic-hybrid (cybrid) cell lines [11,12], and unicellular organ-
isms (bacteria and yeast) easily tractable to genetic manipulations and
biochemical analysis of the ATP synthase [13,14]. The ﬁnal section of
this review highlights several ways in which yeast is being utilized for
the development of strategies to treat ATP synthase deﬁciencies. There
is every reason to believe that with minor modiﬁcations these generalFig. 1. Schematic representation of the bacterial and mitochondrial F1FO-ATP synthases. (A)
four subdomains, i.e. the catalytic headpiece (α3β3), the central rotor stalk (γɛ), the stator st
(γδɛ) contains the additional subunit ɛ. The stator stalk is composed of one subunit b, subun
dimerization.methods can be adapted to therapeutic screens for mitochondrial
disorders that originate from genetic lesions in other proteins of the
respiratory pathway.
2. The F1FO-ATP synthase
2.1. Subunit composition and topology
The overall structure and energy transduction mechanism of the
ATP synthase arewell conserved frombacteria to human. The simplest
form of the enzyme, found in bacteria, is composed of eight different
subunits with the stoichiometry α3β3γ1δ1ɛ1a1b2c10–15 [3,15,16]. The a,
b, and c subunits form the FO component, while the α, β, γ, δ, and ɛ
subunits constitute the F1 part (Fig. 1A and Table 1). The catalytic sites
are located in the α3β3 domain, one in each β subunit. This domain is
connected to the membrane by the so-called central (γɛ) andThe enzyme of E. coli, with a subunit stoichiometry of α3β3γδɛab2c10-12, is organized in
alk (b2δ), and the proton channel (ac10-12). (B) In human mitochondria, the central stalk
its d, F6, f and OSCP. Subunit c is present in 10 copies. Subunits e and g mediate enzyme
Table 1
Subunit composition and nomenclature of the ATP synthases of E. coli, S. cerevisiae and
H. sapiens
Stoichiometry Bacteria Mitochondria
Escherichia coli Saccharomyces cerevisiae Homo sapiens
F1 3 α α α
3 β β β
1 γ γ γ
1 ɛ δ δ
1 – ɛ ɛ
1 δ OSCP OSCP
FO 1 a 6 a
1 – 8 A6L
10–15 c10–12 910 c10
1–2 b2 4 b
1 – d d
1 – h F6
1 – f f
t.b.d. – e e
FO
associated
proteins
t.b.d. – g g
1 – i –
t.b.d. – k –
Regulators 1 – Inh1p IF1
t.b.d. – Stf1p –
t.b.d. – Stf2p –
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constitute an integral membrane proton channel (Fig. 2).
The mitochondrial ATP synthase differs from the bacterial enzyme
in that a number of additional polypeptides contribute to its structure,
regulation and supramolecular organization (Fig. 1B and Table 1).
While there is only one subunit b in the mitochondrial enzyme, three
proteins (d, F6, f) are believed to perform the function of the second
bacterial subunit b [17–19]. The mitochondrial ATP synthase harbors a
third central stalk subunit (ɛ) arranged like a clip around subunits γ
and δ [20]. The subunit A6L, an integral membrane protein unique to
the mitochondrial ATP synthase, is presumed to provide a physical
link between the proton channel and the stator [21]. Two subunits (e,
g) are involved in the supramolecular organization of mitochondrial
ATP synthases [22]. Indeed, the enzyme forms ribbons of homodimers
presumed to be important for the proper ultrastructural organization
of the mitochondrial inner membrane [23–25]. Finally, regulatory
polypeptides (IF1 in mammals; Inh1p, Stf1p, and Stf2p in yeast) have
been shown to inhibit the ATP hydrolysis activity of F1 under certain
conditions [26,27].
The subunit nomenclature is rather complex and confusing. For
example, themitochondrial homologs of the bacterial ɛ and δ subunits
are called δ and OSCP, respectively. Moreover, there are a number of
differences in the designation of the subunits between yeast and
mammals. To avoidmisunderstandings, see the table summarizing the
subunit nomenclature in Escherichia coli, Saccharomyces cerevisiae and
Homo sapiens (Table 1).
2.2. Energy transduction mechanism
The driving force for ATP synthesis derives from the translocation
of protons across the inner membrane through the FO component of
the enzyme. This translocation is mediated by the close arrangement
of subunit a with the c subunits (Fig. 2). The ﬂow of protons through
the FO results in the rotation of the c-ring together with the central
stalk [2–5]. As a result of this rotation, the three catalytic sites of F1
sequentially transit through three states that favor the binding of ADP
and Pi, the synthesis of ATP and its release from the enzyme,
respectively. While the crystal structure of F1 [20,28] and video
microscopy experiments using engineered F1 [29] provide strong
support for this rotary mechanism, the detailed structure of the
proton channel remains largely unknown.However, studies in E. coli have revealed key residues for proton
transport and/or rotation of the c-ring, among which are an acidic
residue (D61 in E. coli, E59 in H. sapiens) in the second transmembrane
helix of subunit c (c-TMH2) and a basic residue in a-TMH4 (R210 in E.
coli, R159 in H. sapiens) [30]. These two residues would be in close
proximity to one another near the middle of the lipid bilayer at the
interface of subunits c and a (Fig. 2). The c-D61 residues facing the
lipid core are supposedly always protonated, whereas those facing
subunit a can be deprotonated and charged. According to Vik et al.
[31], two half proton channels within subunit a allow the c-D61
residues at the subunits c/a interface to be successively deprotonated
and reprotonated (Fig. 2A). The binding of a proton from the periplasm
by the ionized c-D61 is supposed to disrupt its electrostatic interaction
with a-R210 and at the same time the proton of the neighboring c-
D61 would be released and excreted into the cytosol. The newly
deprotonated aspartate could then interact with a-R210 leading to a
one step movement of the ring [31]. A variant of this model based on
pH-induced structural changes of the c protomer in organic solvents
has been proposed [15]. In this model, deprotonation of c-D61 and
release of the proton trigger a 140° rotation of c-TMH2 with
concomitant motion of the ring.
2.3. Biogenesis of the mitochondrial ATP synthase
2.3.1. Transcriptional controls
While most of the mitochondrial proteins are encoded in the
nucleus, few subunits of the energy transduction complexes are
encoded by the mitochondrial genome. Two ATP synthase subunits in
H. sapiens (a, A6L) [32] and three in yeast (6, 8, 9) [33–35] are encoded
by the mtDNA. The expression of the respiratory genes involves a
number of transcriptional factors, exclusively nuclear-encoded, that
act either on the mtDNA or in the nucleus [36]. There is no evidence
for gene-speciﬁc regulation of transcription in both human and yeast
mitochondria. The factors governing nuclear gene expression can be
divided into (i) transcription factors that bind respiratory promoters,
among which are the nuclear respiratory factors NRF-1 and NRF-2,
and (ii) co-activators, e.g. of the PGC family, that do not bind DNA but
rather dock with DNA-bound transcription factors and facilitate
chromatin remodeling [36].
Interestingly, a speciﬁc transcriptional control on subunit c of the
ATP synthase was shown to regulate the abundance of the whole
enzyme in certain human tissues, such as brown adipose tissue (BAT)
[37]. In this tissue, upon cold acclimation, the ATP synthase content is
reduced by 10-fold whereas the mitochondrial respiratory chain
enzymes are still highly abundant. The transmembrane proton
gradient is then preferentially converted into heat instead of ATP
through the activity of the brown adipose tissue-speciﬁc uncoupling
protein UCP1. There are three isoforms of the human subunit c (P1–
P3), which differ only in their targeting sequences. The transcriptional
regulation of the isoform P1 level proved to be crucial for deﬁning the
amount of ATP synthase in brown adipose tissue [37]. A correlation
between the levels of P1-cmRNA and ATP synthase has been observed
for a number of other tissues, e.g. liver and heart [38]. This implies that
the transcriptional regulation of subunit c might be a general
mechanism for deﬁning the amount of the ATP synthase in human
cells in response to various stimuli.
2.3.2. Translational control and mRNA localization
In the mitochondria of S. cerevisiae there are gene-speciﬁc transla-
tional activators bound to the inner membrane that mediate productive
interactions between mitochondrial mRNAs and ribosomes at the
surface of the membrane, suggesting a co-translational insertion of the
mtDNA-encoded proteins [39,40]. These factorsmay regulate the rate of
protein synthesis in mitochondria and/or localize translation to sites
where the mitochondrial gene products can be efﬁciently assembled.
Regarding the ATP synthase, Atp22p was recently reported to
Fig. 2. Schematic representation of the interaction between the a and c subunits in the E. coli ATP synthase. (A) The c subunits are arranged in a ring that contacts the subunit a. The a
subunit supposedly provides two half channels for proton ﬂow across themembrane (indicated by the dotted line). The a-R210 and c-D61 residues near themiddle of the lipid bilayer
are of critical importance for the function of the proton channel (see text). (B, C) 3D-folding model of subunits a and c of E. coli. The last four transmembrane segments (aTMH2-5) of
subunit a and the c subunits are depicted according to Rastogi and Girvin [15] (Protein Data Bank entry 1C17). Only trace backbones of the proteins are shown. The critical a-R210 and
c-D61 residues are indicated in dark- and light-blue, respectively. Other important residues for the proton channel (according to the model of R.H. Fillingame [30]) are accentuated in
orange. (C) View from the periplasm.
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is no evidence for the existence of gene-speciﬁc translational activators
in human mitochondria. It remains possible, however, that the mtDNA-
encoded proteins are synthesized in the vicinity of the inner
mitochondrial membrane also in human cells.While it is widely accepted that the nuclear-encoded mitochon-
drial proteins are synthesized on free ribosomes in the cytosol before
they are imported into mitochondria [42], there is recent evidence
that a subclass of proteins is translated on mitochondria-associated
ribosomes [43]. Regarding the ATP synthase, the mRNAs of a number
190 R. Kucharczyk et al. / Biochimica et Biophysica Acta 1793 (2009) 186–199of subunits (α, β, γ in yeast [44]; β in H. sapiens [45]) were found to be
preferentially, if not exclusively, located on the mitochondrial surface.
The subcellular addressing of these mRNAs requires cis-acting
elements located in their 3′UTRs that are apparently required for a
proper interaction with the translational machinery [46]. The binding
of putative regulatory proteins to the 3′UTR is thought to be
responsible for the translation masking of β-F1 mRNA observed
during liver development and in kidney cells [47,48]. Thus, in addition
to the transcriptional regulation of the P1 subunit c gene, speciﬁc
translational controls on other ATP synthase subunits may also play a
role in determining the abundance of this enzyme in human cells.
2.3.3. Assembly
The current hypothesis regarding the assembly of the ATP synthase
is mainly based on the isolation and analysis of assembly-deﬁcient
yeast mutants and on data on its subunit topology [6,49]. It is thought
that, after synthesis on mitochondrial ribosomes, subunit 9 (or Atp9p)
oligomerizes to form a 10 subunits ring to which the F1 sector is
subsequently attached. The c-F1 pre-complex is thought to be further
completed by the addition of Atp8p, followed by Atp4p, the other
components of the stator arm, and ﬁnally Atp6p (Fig. 3). The addition
of Atp6p at a late stage of the assembly may prevent the formation of
partially assembled enzymes that could dissipate the mitochondrial
membrane potential through FO-mediated proton leaks [50]. How-
ever, the possibility of an alternative pathway [51] cannot be ruled out,
inwhich the assembly of the FO-partmay proceed through to the point
where subunit 6 and the stator stalk join the c-ring, followed by the
integration of the F1-subcomplex.
Biogenesis of the F1 requires the mitochondrial chaperone Hsp60p
and at least three factors in yeast: Atp11p, Atp12p [52] and Fmc1p [53].
Atp11p and Atp12p, which are conserved in H. sapiens [54], function as
molecular chaperones that probably stabilize unassembled α-F1 and β-
F1 subunits by shielding their hydrophobic surfaces [55,56]. In theFig. 3. Assembly of the yeast mitochondrial ATP synthase. The assembly proceeds in a sequent
headpiece, the ring of subunits 9, and the central stalk, are pre-assembled and then attached
Subunit 6 is incorporated as a last step to render the enzyme functional. ATP synthase monabsence of either Atp11p or Atp12p, the α-F1 and β-F1 aggregate within
large inclusion bodies in the mitochondrial matrix [52,57].
The assembly of the FO also requires at least three proteins in yeast:
Atp10p [58], Atp23p [58–60] and Atp25p [61]. The latter is required
for the expression of Atp9p, and was proposed to be involved in the
formation of the subunit 9 ring [61]. No human homolog has been
described so far. The two other factors are required for the
incorporation of Atp6p into the ATP synthase complex. The Atp6p
subunit is synthesized with an N-terminal pre-sequence of 10 amino
acid residues [62] that is cleaved by Atp23p, a membrane-bound
metallo-protease with the characteristic HXXHH motif [59,60,63].
Interestingly, mutations in this motif prevent the maturation of the
subunit 6 precursor, but not the assembly of the ATP synthase. Thus, in
addition to its processing activity, Atp23p must provide another
important function in the assembly of the FO. In H. sapiens, there is a
clear homolog of Atp23p while the human subunit a lacks an N-
terminal extension [59,63]. Therefore, the human ATP23 might either
have retained only a chaperone function towards subunit a, or it might
cleave other as yet unidentiﬁed substrates [59,63], or it might fulﬁll
both tasks as described for several other mitochondrial proteases.
However, there is no direct evidence for its involvement in the
assembly of the human ATP synthase.
3. Disorders related to primary defects in the mitochondrial ATP
synthase
Patients suffering from disorders related to primary defects in the
F1FO-ATP synthase present with a wide variety of symptoms. Due to
the dual genetic origin of mitochondria, underlying mutations are
located either in nuclear or mitochondrial DNA. While the mitochon-
drial mutations have been found in the two mitochondrially-encoded
subunits of the enzyme (a and A6L), only one of the nuclear mutations
has been identiﬁed so far (Table 2).ial order and is assisted by speciﬁc chaperones (indicated above arrows). Initially, the F1-
to one another. Next, subunit 8 and the peripheral stalk are added to the pre-complex.
omers can be further assembled into dimers involving subunits e and g.
Table 2
Summary of reported pathogenic mutations responsible for ATP synthase deﬁciencies
Gene Mutation Clinical presentation/ References
Nucleotide
change
Amino acid
substitution
manifestation
ATP6
(mtDNA)
T 8851 C W 109 R FBSN [95]
T 8993 G L 156 R NARP, MILS [68, 74, 76–78,
80–83, 87, 88]
T 8993 C L 156 P NARP, MILS [84–88]
T9101 C L192T LHON [103]
T 9176 G L 217 R NARP, MILS [89]
T 9176 C L 217 P NARP, MILS [75, 91–94]
T 9185 C L 220 P MILS [96, 97]
T 9191 C L 222 P MILS [96]
ΔTA 9205 –a Severe
encephalopathy
[99, 100]
ATP8
(mtDNA)
G 8529 A W 55 Xb Cardiomyopathy,
neuropathy
[106]
ATP12
(nuclear
DNA)
TGG94NAGG W 94 R Encephalomyopathy [64, 65]
a Two basepair deletion in the ATP6 stop codon.
b Nonsense mutation in codon 5.
Fig. 4. Positions of the pathogenic mutations in ATP6. 3D-folding model of the E. coli
subunit a (the last four transmembrane segments) according to Rastogi and Gavin [15]
(Protein Data Bank entry 1C17). The catalytic arginine a-R210 is represented in blue. The
E. coli residues corresponding to the mutated ones in the human subunit a in NARP,
MILS and FBSN (see Fig. 5) are represented in red. The corresponding mutations and
residue exchanges in the human subunit a are indicated.
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The ﬁrst defect in the ATP synthase with a conﬁrmed nuclear
origin was reported by Houstek and colleagues in the case of a child
with severe lactic acidosis, cardiomyopathy and hepatomegaly, who
died 2 days after birth [64]. The ATP synthase content was decreased
by 70–80% in all analyzed patient's tissues, whereas the respiratory
chain complexes were essentially unaffected. The structural genes of
the ATP synthase did not show anymutation or expression deﬁcit. All
these ﬁndings indicated that the low content of the enzyme was due
to a mutation in some factor speciﬁcally involved in ATP synthase
assembly. Since then, several similar cases have been reported [9].
Unfortunately, the nuclear mutations causing the above-mentioned
diseases remain mostly unknown. All these patients have been
screened for mutations or altered levels of expression in the
conserved assembly factors ATP11 and ATP12, initially described in
yeast. Only in one case was a homozygous point mutation found in
the ATP12 gene [65]. This implies for the other cases the etiological
involvement of as yet unidentiﬁed ATP synthase assembly factors.
3.2. ATP synthase-based diseases of mitochondrial genetic origin
3.2.1. Pathogenic mutations of the mitochondrial ATP6 gene
Several point mutations in the ATP6 gene (Figs. 4 and 5; Table 2)
have been associated with a group of maternally inherited, early onset
neurodegenerative syndromes [10,66,67]: NARP, MILS and FBSN. The
name of the NARP syndrome is derived from its main clinical
manifestations, Neuropathy, Ataxia, and Retinitis Pigmentosa [68].
MILS is the maternally inherited form [69] of the Leigh syndrome (LS),
a fatal encephalopathy of infancy [70], that has been associated with
mutations in nuclear-encoded subunits of complex I and IV [71–73], as
well as pyruvate dehydrogenase [74]. A similar, but less progressive
syndrome is the ‘Familial Bilateral Striatal Necrosis’ (FBSN) [75].
3.2.1.1. Mutations at position nt8993. The most common and best
studied of the pathogenic ATP6 mutations is T8993G. This mutation
leads to replacement of a highly conserved leucine by arginine at
position 156 of subunit a [68] (Fig. 5). In patient tissues, the thousands
of molecules of mtDNA per cell consist of a mixture of both mutated
and wild-type mtDNA, a situation that is referred to as heteroplasmy.
Different mutation loads result in distinct clinical presentations. A
level of approximately 70% of mutated mtDNA has to be exceeded in
order to provoke clinical symptoms. Patients with a mutation loadwithin the range of 70–90%mainly develop the NARP syndrome, while
a level of mutated mtDNA higher than 90% usually results in the
manifestation of MILS [76].
Analysis of patient's ﬁbroblasts and cybrids has shown that high
loads of T8993G result in a 50–90% decrease in the rate of ATP
synthesis [77,78]. Initially it was proposed that the decrease in ATP
production could be at least in part due to defects in assembly and/or
stability of the ATP synthase [12,77,79]. However, a recent thorough
study on ATP synthase assembly in cultured human cells homoplasmic
for T8993G failed to show any assembly defect. This would suggest
that this mutation may rather cause a local disruption of the enzyme's
proton channel [80]. This view is supported by the topological model
introduced in section II.2, inwhich the leucine 156 (L207 in E. coli) is in
close proximity to other residues critical for proton translocation, both
in subunit a and c (Figs. 2 and 4). Still, the impact of the T8993G
mutation at the molecular level remains controversial. Some have
claimed that the proton ﬂow through the FO is not tightly coupled to
ATP synthesis in the mutated enzyme [67], while others have
proposed a blockage of the proton channel [78]. The reasons for the
different outcomes of the studies on the inﬂuence of T8993G on the
assembly of the ATP synthase are still unknown. Special features
regarding the type of sample analyzed (biopsies of patient's tissues,
cultures of ﬁbroblasts and cybrids) might be responsible for the
apparent discrepancy.
ATP hydrolysis activity assays on disrupted mitochondrial mem-
branes indicate that the T8993G mutation does not affect the reverse
functioning of the ATP synthase [69,77,81,82]. Similar experiments
carried out on a yeast model of the T8993G mutation conﬁrmed these
results [13]. However, the further analysis of ATP hydrolysis sustained
proton pumping (assayed on intact mitochondria) in this model
revealed a clear alteration in the mitochondrial membrane potential.
So far, only one study has addressed this in human NARP cells, and
failed to detect signiﬁcant differences [83]. This might however be
attributed to the use of inverted mitochondrial membranes instead of
intact mitochondria, which in this case were derived from patients'
platelets with a 15–90% heteroplasmy. Moreover, the latter implies the
presence of wild-type ATP synthase complexes in the analyzed
submitochondrial particles, which might sufﬁciently account for the
observed proton pumping activity. Although yeast and human ATP
synthases may be differently affected by the T8993G mutation, the
results obtained in those studies imply the need for further analyses,
carried out in more suitable conditions, in order to draw ﬁrm
conclusions about the inﬂuence of mutations on the reverse
functioning of the human ATP synthase.
Fig. 5. Alignment of subunits a from different species. The C-terminal part of the human subunit a (HUMAN) is aligned to those of E. coli (ECOLI), S. cerevisiae (SACCH), Alligator
mississippiensis (ALLMI), Arabidopsis thaliana (ARATH), Brachydanio rerio (BRARE), Caenorhabditis elegans (CAEEL), Ciona intestalis (CIOIN), Drosophilia melanogaster (DROME), Neur-
ospora crassa (NEUCR), Podospora anserina (PODAN), and Xenopus laevis (XENLA). Amino acid changes in NARP, MILS, and FBSN are indicated by green dots. The catalytic arginine (R159
in human, R210 in E. coli) is represented in red. The regions corresponding to the putative transmembrane segments (TMH3-5) of the E. coli subunit a [30] are indicated by bars below
the alignment. Conserved residues are highlighted in color (red: 100% identity or conservative change; yellow:≥60% identity or conservative change).
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Leu-156 to Pro – also accounts for cases of NARP syndrome and MILS,
but usually results in a milder clinical presentation than T8993G
[84,85]. Consistent with this, the rate of ATP synthesis was found to be
only slightly diminished in patients' ﬁbroblasts or cybrids containing
high loads of T8993C (up to 100%), in apparent contrast to the T8993G
cells [86]. However, in a recent study of several children with a 95%
load of this mutation, signiﬁcant (50%) decreases in activity and
impaired assembly/stability of complex V have been observed in
muscle biopsies [87]. Thus, a direct impact of ATP undersupply cannot
be ruled out, even though it has been suggested that cellular oxidative
damage due to an increased level of reactive oxygen species (ROS)may
be the main pathogenic factor in T8993C patients [88].
3.2.1.2. Other pathogenic ATP6 mutations. Several further mutations in
the ATP6 gene have been reported in patients presenting with
symptoms characteristic of NARP/MILS (Table 2; Figs. 4 and 5).
T9176G/T9176C. These mutations result in a replacement of the
conserved leucine 217 by either arginine (T9176G) or proline
(T9176C) [75,89,90]. A high mutation load (95%) of T9176G in
patient's ﬁbroblast was associated with a massive reduction of the
ATP synthesis rate ( b 20% of control) [89].Modeling thismutation in
E. coli conﬁrmed this observation, as neither signiﬁcant ATP
synthesis, hydrolysis nor proton pumping activity was detectable
[14]. The T toC transition at this position results in clinical symptoms
only at very high levels of heteroplasmy and usually causes a milder
phenotype [75,91,92]. In addition, the rate of ATP production was
basically unaffected in the patients described [75]. However, there
are also reports of fulminant progression of Leigh syndrome in
patients harboring the T9176Cmutation [93,94]. Future studies will
be needed to decipher the molecular function of Leu217.
T8851C. The T8851C mutation, which results in the replacement of
the conserved tryptophan 109 in the second transmembrane helix
by arginine, has so far been reported only in a single case [95]. No
thorough analysis of the impact of this mutation on the ATP
synthase has yet been carried out
T9185C/T9191C. Two novel missense mutations in the ATP6 gene,
T9185C and T9191C, have recently been described [96]. These
mutations cause the substitution of either of the conserved leucine
residues in the ﬁfth transmembrane helix by proline at positions
220 and 222, respectively. In spite of a high mutation load, patients
harboring the T9185Cmutation present with a relativelymild form
of Leigh syndrome [96,97]. The analysis of patients' lymphoblast
mitochondria revealed that the ATP synthesis rate is not affected,
while the ATP hydrolysis sustained proton pumping activity is
decreased by 30% [97]. In contrast, the T9191C mutation was
associated with a distinctly more severe clinical phenotype with a
reduced respiratory rate and more pronounced impairment of the
ATP hydrolysis activity [96].
ΔTA9205. One mutation of a different kind is the two-nucleotide
micro-deletion (ΔTA9205) within the stop codon of the ATP6 gene
that modiﬁes the processing site within the tri-cistronic ATP8-
ATP6-COX3 transcript [98]. It is a very raremutation, so far reported
in only two cases [99,100]. Even though both cases were nearly
homoplasmic (N 98%), their clinical manifestations were very
different. In line with that, a detailed molecular and biochemical
analysis of cultured ﬁbroblasts from both patients revealed major
differences [100–102]. In themore severely affected patient several
alterations were observed: a reduction of subunit a biosynthesis;
an accumulation of incompletely assembled ATP synthase; a 3-fold
decrease in mitochondrial ATP production; a reduction in COXactivity by around 85%. These results have been attributed to the
impaired maturation of the ATP8-ATP6-COX3 transcript [100]. The
other patient, however, merely exhibited a reduction in the steady
state level of the ATPase 8- and 6-encoding bi-cistronic mRNA,
while biogenesis and function of the ATP synthase appeared
unaffected [101,102]. To date, there is no explanation for the
pronounced discrepancy between these two patients. One can only
speculate that the phenotypic differences may be due to further
mutationswithin themtDNA, or to the presence of a compensatory
mechanism in the less severely affected patient, which could
potentially be mediated by an unknown factor involved in post-
transcriptional processing and translation of the ATP6 mRNA.
Finally, one further mutation in the ATP6 gene has been ascribed to
a different clinical presentation. The T9101C mutation has been
reported in a patient suffering from Leber's hereditary optic
neuroretinopathy (LHON) [103], a maternally inherited eye disease
resulting in bilateral optic atrophy in young adults [104]. In this case a
reduction in the efﬁciency of oxidative phosphorylation, attributed to
a proton leakage, has been observed [103,105]. It is, however,
surprising that the replacement of isoleucine 192 by threonine in
this weakly conserved region of subunit a results in such a
bioenergetic alteration, as threonine is the prevailing residue at this
position for many other species, including cattle, mice and rats (Fig. 5).
3.2.2. A pathogenic mutation of the mitochondrial ATP8 gene
Recently, a homoplasmic nonsense mutation in the mitochondrial
ATP8 gene has been detected in a 16-year-old patient with apical
hypertrophic cardiomyopathy and neuropathy [106]. The mutation is
located in the overlapping region of ATP6 and ATP8 (nucleotides 8527–
8572). It results in a silent change of the initiator methionine codon of
ATP6, and induces a premature stop codon in ATP8, leading to a
truncated A6L protein that lacks the last 14 amino acids. The analysis of
patient's ﬁbroblasts, muscle tissue and derived cybrids showed a
decreased mitochondrial ATP synthesis rate, a lack of fully assembled
complex V and an accumulation of ATP synthase subcomplexes [106].
These results reveal the importance of the C-terminal region of theATP8
gene product (A6L) for the assembly/stability of the ATP synthase.
3.3. Secondary pathogenic effects
The phenotypic presentations observed in several of the previously
described ATP synthase deﬁciencies cannot be accounted for simply
by a lack of ATP provision. Attention has therefore turned to the quest
for secondary effects that could be involved in the pathogenic
mechanisms.
A well-documented example is the investigation of the role of
reactive oxygen species (ROS) in mitochondrial diseases. Under normal
physiological conditions, 2–4% of the oxygen consumed by mitochon-
dria are converted to superoxide anion instead of water due to
unproductive electron transfer within complexes I and III [107–110].
When the respiratory chain is slowed down, more electrons are
diverted from their normal pathway, resulting in an elevated ROS
production. Such a situation can be found in the case of ATP synthase
deﬁciencies, as in tightly coupled mitochondria a limited rate of ATP
synthesis results in a high membrane potential, and hence in a slowing
down of the electron transfer rate along the respiratory chain [111].
A study of cybrid cells containing various proportions of T8993G
revealed the importance of cellular oxidative damage in NARP/MILS,
as evidenced by the ability of various antioxidant agents, which
promote ROS scavenging, to signiﬁcantly improve mitochondrial
respiration and ATP synthesis in the T8993G cells [112]. Other reports
using cultures of ﬁbroblasts from patients with a high level of T8993G
(N 90%) appear to show a dramatic increase in superoxide dismutase
activity (SOD), mediated by the actin-Nrf2 signaling pathway, and in
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by perﬂuoro-tri-phenyl, an antioxidant spin-trap molecule. Thus, in
addition to energy deprivation, patients with ATP synthase deﬁcien-
cies may suffer from a chronic up-regulation of ROS that may override
their antioxidant defense capacity [115].
In an attempt to gain a more global view of the cellular
consequences of ATP synthase dysfunctions, microarray analyses
have been performed to evaluate the associated nuclear transcrip-
tional response [116–118]. The results of such studies may direct our
attention to other so far unrelated cellular pathways, as exempliﬁed by
an up-regulation of genes related to the unfolded protein response
(UPR) and to the cell cycle in a recent report using cybrid cells
harboring a T8993G mutation [116].
Considering mitochondria beyond their bioenergetic function
might be crucial for a complete understanding of pathogenic path-
ways at a molecular level. In recent years mitochondria have come to
be seen as highly dynamic organelles that continuously move, fuse
and divide [119]. Furthermore, it has been established that mitochon-
drial membrane dynamics can modulate mitochondrial and cellular
functions [120]. In humans, mutations of genes encoding components
of the mitochondrial fusion/ﬁssion machineries are associated with
various neuropathies [121–123]. In addition, mitochondrial dysfunc-
tion provokes changes in mitochondrial morphology as exempliﬁed in
several models of mitochondrial pathologies [124], indicating a close
relationship between membrane dynamics and energy metabolism.
Furthermore, oligomerization of the ATP synthase apparently plays an
important role in the structural organization of the inner mitochon-
drial membrane in cristae [23,25,125,126]. Therefore, changes in the
morphology and ultrastructure of mitochondria may also contribute
to the underlying pathogenic mechanisms of ATPase-based diseases.
Recently, several reports have revealed that the F1FO-ATP synthase
is also present in the plasma membrane in various cell types. At this
location it is thought to play a role in regulating angiogenesis and as a
receptor for apolipoprotein A-I [127–132]. It is possible that a
concomitant impairment of an ectopic function of the ATP synthase
is involved in the pathogenesis of ATP synthase-based diseases.
4. Current and prospective therapeutic strategies for ATP synthase
deﬁciencies
In spite of the considerable progress in our understanding of the
molecular mechanisms underlying mitochondrial diseases, the avail-
able therapeutic approaches are still extremely limited and there is no
speciﬁc treatment for ATP synthase deﬁciencies.
4.1. Pharmacological approaches
The administration of drugs in ATP synthase-based diseases is
aimed at treating the symptoms (e.g. seizure control by antic-
onvulsants), eliminating noxious metabolites and supplying with
oxygen radical scavengers (reviewed in [133,134]). The speciﬁc tar-
geting of drugs, especially antioxidants, to mitochondria has recently
received considerable attention [135–138]. The role of all these sup-
portive therapeutic strategies has however not been demonstrated as
there is no clear evidence supporting the use of any of these treat-
ments [139,140].
4.2. Genetic-based therapeutic strategies
The current inadequacy of treatment for patients with mitochon-
drial disorders highlights the need to develop gene therapy strategies.
In addition to the many unsolved challenges for gene therapy in
general, the genetic modiﬁcation of mtDNA encounters further
difﬁculties, such as the presence of multiple mtDNA copies per cell,
heteroplasmy and the complexity of manipulating the mitochondrial
genome in living cells. Nevertheless, several experimental strategieshave been developed [133,134,141–145], of which two will be
discussed below.
4.2.1. Complementation through allotopic expression
One possible gene therapy for disorders resulting from mutations
in the mtDNA exploits the allotopic expression of mtDNA-encoded
polypeptides. In this approach, initially established in yeast [146,147],
a protein normally encoded by the mtDNA is synthesized in the
cytosol from an alternative nuclear version of its gene fused to a
mitochondrial targeting sequence (MTS).
A critical element in this approach is the efﬁcient mitochondrial
import of the allotopically expressed protein, and its assembly in the
dedicated protein complex. In order to achieve this, it appears
essential to select a suitable MTS, as the proteins encoded by the
mtDNA are very hydrophobic, and this is thought to limit their import
efﬁciency.
The allotopic expression strategy has been used in an attempt to
remedy the ATP synthase deﬁciency resulting from the T8993G
mutation. Initial attempts have been made by fusing typical human
MTSs (e.g. those of COX8 and isoform P1 of ATP synthase subunit c)
N-terminally to the human subunit a. These constructs were found
to be transported into mitochondria with a rather low efﬁciency, and
only a modest recovery of the NARP cells was observed, if any at all
[148]. Another experiment was conducted with the Atp6 subunit of
Chlamydomonas reinhardtii. In this organism the Atp6 subunit is
naturally encoded in the nucleus with a very long MTS (107 amino
acids) that is believed to facilitate its transport into mitochondria
[149]. In this case too, a very weak complementation was reported
[150]. Furthermore, the allotopic expression of the Chinese hamster
ATPase6 in wild-type Chinese Hamster Ovary (CHO) and T8993G
cybrid cells was reported. In this study, an oligomycin resistance
mutationwas included in the nuclear version of ATPase6 gene, which
apparently gave the engineered cells a 1000-fold increase in
oligomycin resistance [151]. A more recent study has cast all these
results into doubt, pointing out that essential controls were missing
and that no convincing conclusion could therefore be drawn, as the
observed partial complementation could be of unspeciﬁc origin
[152].
Finally, a very recent study using ﬁbroblasts with a 95% hetero-
plasmy for the T8993G mutation investigated whether translation on
mitochondria-associated ribosomes improves the allotopic expression
of human subunit a. To this end, the authors equipped an engineered
ATP6 gene with the MTS and 3′UTR of the SOD2 gene. These elements
were shown to direct the SOD2 mRNA to the mitochondrial surface
[153]. The translated protein was more efﬁciently transported into
mitochondria, was able to restore the ATP synthesis defect and
allowed survival in a galactose medium. However, the 3′UTR of SOD2
was not essential for complementation and no direct evidence was
provided for the association of the hybrid ATP6 transcript with
mitochondria.
Thus, even though promising preliminary studies raise hopes for
the allotopic expression strategy, further experiments are required to
settle the questions raised by the experimental data obtained so far.
4.2.2. Manipulation of heteroplasmy
One characteristic feature of mitochondrial diseases is the relation
between the manifestation and gravity of symptoms and the cellular
ratio of mutant to wild-type mitochondrial DNA [154–156]. The
manipulation of this ratio appears to be a desirable therapeutic target.
Several such approaches in this direction have been described in
recent years [141,144].
One idea is to speciﬁcally inhibit the replication of mutant
mitochondrial DNA through the sequence-speciﬁc binding of
peptide nucleic acids (PNAs) [157–160]. Another concept emerges
from a recent study that has demonstrated the use of a chimeric zinc
ﬁnger methylase for the sequence-speciﬁc modiﬁcation of mtDNA
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(ZFPs) with a nuclease activity to speciﬁcally disrupt mutated
mtDNAs [161]. A similar approach derives from the fact that certain
pathogenic mutations create unique restriction sites in the mtDNA
(e.g. T8993G results in a unique SmaI/XmaI site). It has been shown
that targeting the corresponding restriction endonucleases to
mitochondria induces the speciﬁc elimination of mutated mtDNA
[162–164]. Such an approach resulted in a successful shift of
heteroplasmy in muscle and brain tissues of mouse models
containing speciﬁc polymorphic variants of mtDNA [165]. This
strategy is however limited, as the probability of a randommutation
creating a unique restriction site in the mtDNA sequence is ex-
tremely low.
These approaches could achieve the elimination of the mutated
alleles, followed by the repopulation with wild-type mtDNA. This in
turn could prevent the onset or alleviate the symptoms of a disease
associated with heteroplasmic mtDNA mutations. It must be stressed
that all of these techniques are still in an experimental phase and
encounter a number of technical problems. Yet they potentially
provide the basis for the development of novel and effective
treatments.
5. Yeast as a model system for the study of ATP synthase-based
diseases
5.1. Yeast models of ATP synthase-based diseases
Due to its ability to conduct ethanolic fermentation, baker's yeast
(S. cerevisiae) can survive mutations that impair mitochondrial
respiration [166]. This capacity makes it an invaluable tool in
mitochondrial research, as it allows for the identiﬁcation of genes
required for the biogenesis and function of mitochondria [167,168].
Hence, over the past 25years, respiratory-deﬁcient yeast mutants have
revealed hundreds of nuclear genes with mitochondrial functions
[168,169]. Many of these genes have human orthologs, of which
several have been implicated in various diseases [169], e.g. the
assembly factor ATP12 concerning the F1FO-ATP synthase [9,65].
Ongoing studies in yeast promise to uncover novel factors, thus
providing the basis for identifying as yet unrecognized nuclear
mutations, which account for ATP synthase related mitochondrial
disorders.
Furthermore, S. cerevisiae proved to be a valuable model system
for deﬁning the impact of humanmtDNAmutations onmitochondrial
structure and function [13,170]. Using a biolistic (biological ballistic)
procedure, deﬁned mutations can be introduced into the yeast
mtDNA [169]. A homoplasmic population is easily obtained, due to
the natural instability of heteroplasmy in this organism. It was long
believed that deleterious mutations in the yeast mitochondrial ATP
synthase genes would destabilize the mtDNA [171]. However, we
have shown recently that mutations in the yeast mitochondrial ATP6
gene have only a very limited impact on mtDNA stability, even if they
severely compromise the FO [13,172]. While both in humans and in
yeast the T8993G mutation drastically reduced the rate of mitochon-
drial ATP synthesis due to a local disruption within the ATP synthase
proton channel [13,80], the E. coli model of this mutation showed a
complete lack of assembly of subunit a [14,173]. The dual genetic
origin and the more sophisticated structure of mitochondrial ATP
synthase, with at least 10 subunits not present in the bacterial
enzyme, may account for the observed differences. By contrast,
mutations modeled in yeast have a higher chance of mimicking
mutations found in the human mitochondrial ATP synthase as the
two enzymes are highly similar, not only in their structure but also in
their assembly pathway. Yeast models of four other ATP6 mutations
(T8993C, T9176C, T9176G and T8851C) found to be pathogenic in
humans have been constructed and analyzed (Kucharczyk and di
Rago, in preparation).5.2. Yeast-based approaches for seeking mechanisms for remedying ATP
synthase deﬁciencies
5.2.1. Genetic suppressors
Yeast can also be used to uncover potential rescuing mechanisms
that might enable the treatment of patients suffering from mitochon-
drial diseases [174]. One approach aims to discover genetic suppres-
sors. The term suppression designates the reversal of a mutant
phenotype via an additional mutation that does not restore the
original genotype. The suppressor mutation can be located (i) within
the same gene as the primary mutation, thus being referred to as
intragenic suppression; (ii) in a different gene within the same
genome, i.e. intergenic suppression; and (iii) in the case of the
mitochondrial energy transduction system, it can also be interge-
nomic, as both the nuclear and the mitochondrial genomes encode for
components of the oxidative phosphorylation complexes. Suppression
can also be the result of an increased gene dosage (multicopy
suppressors).
The discovery of genetic suppressors may disclose unpredictable
connections between different cellular pathways. Using this approach,
we have recently discovered a suppressor mechanism of special
interest for mitochondrial pathologies. In our study, we used a
primary mutation (Δfmc1) resulting in a major decrease (N 90%) in the
ATP synthase content [53], as observed in patients bearing nuclear
mutations in ATP12 and other yet unidentiﬁed genes. A completely
unexpected suppressor was Odc1p [175], a member of the mitochon-
drial carrier family, which exchanges intermediates of the TCA cycle
across the inner membrane [176]. Odc1p transport activity is a
controlling step in the TCA cycle. A 10-fold increase in Odc1p content
was found to increase ATP production through mitochondrial
substrate-level phosphorylation, and to subsequently lead to de-
repression of the biogenesis of the respiratory chain complexes [175].
Alternative ATP synthesis via this pathway is sufﬁcient to sustain
strong respiratory growth despite of a very low content in ATP
synthase. This suppressor mechanism was also found to substantially
improve the respiratory capacity of the yeast NARP T8993G model
(Rak and di Rago, in preparation). Thus, metabolic suppression is
certainly a lead worth following to explore therapeutic solutions for
mitochondrial diseases.
5.2.2. Pharmacological suppressors
Although yeast has been extensively used for the study of
mitochondrial diseases, and several yeast models of human mito-
chondrial diseases are available, the pharmacological approach has so
far been neglected. We consider such an approach to be very
promising, as available chemical libraries comprised of tens of
thousands of substances can be tested in a rather short period of
time. Such a screening employing a yeast-based assay has already
been successful in the selection of drugs active against mammalian
prions [177].
Using such an approach, promising molecules active on yeast
models of ATP synthase deﬁciencies have already been isolated (E.
Couplan andM. Blondel, unpublished). These drugs will be next tested
on mammalian cells (ﬁbroblasts, cybrids) that model the same
diseases. Another interesting model for testing the selected drugs is
a Drosophila melanogaster mutant presenting a neuromuscular
disorder, which originates from sequence modiﬁcations in the ATP6
gene [178]. Yet, to our knowledge, this is the only animal model of ATP
synthase deﬁciency available to date.
6. Conclusion
In spite of the recent progress in our understanding of the
assembly and function of the mitochondrial F1FO-ATP synthase, the
pathogenic mechanisms of ATP synthase disorders are not yet well
understood. Furthermore, there are very fewways of treating the large
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on the molecular causes of these diseases by using alternative model
systems in studying the primary and secondary effects of ATP synthase
deﬁciencies. In the near future, the further development of novel
therapeutic approaches, and of sophisticated strategies in the search
for alternative therapeutic pathways, promises to improve the outlook
for people suffering from these mainly fatal diseases.
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